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NKG2D is an activating receptor present in all human NK cells, CD8+ T cells, and in certain
populations of CD4 T cells, and engagement of this receptor with its ligands is a crucial step in
the regulation of both innate and specific immune responses [for review, see Ref. (1)]. NKG2D
recognizes two families of MHC-related molecules, whose expression is, in general, upregulated
when the cells suffer different types of stress including infection and tumorigenesis. In fact, a
large variety of primary tumors and tumor-derived cell lines express NKG2D-ligands and, in
the last few years, many reports have established correlations between the presence of NKG2D-
ligands in cancer patient serum and disease prognosis [for review, see Ref. (2)]. The presence
of NKG2D-ligands in serum is related to another important feature of these molecules: they can
be released to the supernatant by either metalloprotease cleavage or incorporated in nanovesicles
(exosomes), depending on their biochemical features [for review, see Ref. (3)]. However, it is
still not understood why NKG2D-ligands are, in some instances, secreted while in other cases
they remain at the cell surface, and understanding the cellular “decisions” on the pathways fol-
lowed by these molecules will be of crucial importance in the choice of novel therapies based on
NKG2D, such as monoclonal antibodies or NKG2D-CARs [for review, see Ref. (4)], since soluble
ligands could interfere with these therapies in different manners depending on their biological
form. In this sense, detailed study of the differential features of each individual NKG2D-ligand
is still needed and investigation of the mechanisms used by different viral gene products to
interfere with NKG2D-ligand expression will likely be critical in uncovering these cell biology
issues.
Human NKG2D-Ligands and Immune Regulation
NKG2D-ligands belong to two genetic families withmultiplemembers: themajor histocompatibility
complex class I-related chain (MIC)A/B and UL16 binding protein (ULBP) one to six molecules,
also known as retinoic acid early transcripts (RAETs) [for review, see Ref. (5)]. Although both
families of NKG2D-ligands are related to MHC molecules and their expression is increased
after stress, many differences are observed in their biochemical and cell trafficking properties.
Moreover, individual ULBP molecules and MICA/B alleles can share functional characteristics
that are not generally conserved within their genetic family. For example, most MICA/B alleles
are transmembrane proteins whereas ULBPs have glycosyl-phosphatidyl-inositol (GPI) anchors.
However, MICA is a highly polymorphic gene and some of the most frequent alleles, the group
known as MICA5.1 whose principal component is MICA*008, contain a frame-shift mutation
in the transmembrane region that introduces an early stop codon. These changes mean that
MICA5.1 alleles attach to the plasma membrane via a GPI anchor (6), like most of the ULBPs
(Figure 1). MICA*008 also differs from other MICA alleles in that it has an extremely slow
maturation rate (6, 7) and differs in the N-glycosylation requirements for cell trafficking (8).
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FIGURE 1 | NKG2D-ligands belong to two genetic families with
multiple biochemical and cell biology features. The two genetic families
of NKG2D-ligands, MICA/B (major histocompatibility complex class I-related
chain) and ULBPs (UL16-binding proteins), encode proteins with different
membrane attachments [transmembrane (TM) and glycosyl-phosphatidyl-
inositol (GPI)] and different mechanisms for release to the extracellular milieu
[exosomes versus metalloprotease (MMP) cleavage]. However, not all the
members of one of these genetic families of NKG2D-ligands share the same
biochemical characteristics. NKG2D-ligands are also differentially recognized
by viral proteins and miRNAs that interfere with the immune response. As an
example, the human cytomegalovirus evasion molecules targeting
NKG2D-ligands (proteins in blue, miRNA in orange) are depicted.
Functionally, the difference inmembrane anchoring ofMICA*008
alters its mechanism of release to the extracellular milieu and
affects the modulation of the immune response, since multimeric,
exosomal MICA*008 are more potent downmodulators of the
NKG2D receptor than soluble monomeric MICA molecules (9)
and could be more immunogenic (10). Thus, it is important
to study the biology of individual NKG2D-ligands separately
to understand their involvement in immune recognition and
evasion, especially since the use of drugs to modulate immune
responses, by regulating NKG2D-ligand release, could also have
different outcomes depending on the release mechanism; for
example, inhibition of metalloproteases leads to incorporation
into exosomes of certain NKG2D-ligands (11).
Study of Viral Immune Evasion Strategies
Can Aid Understanding the Heterogeneity
in the Cell Biology of NKG2D-Ligands
A striking feature of the biology of theMICA*008 allele is its resis-
tance to most of the described viral immune evasion strategies.
Human cytomegalovirus (HCMV), for example, encodes several
viral proteins and miRNAs that interfere with NKG2D-ligand
expression [(12–14) and references therein], yet MICA*008, was
resistant to the MICA binding viral protein UL142 (15, 16),
and was not downregulated upon infection with HCMV strain
AD169VarS (17, 18). Indeed, MICA*008 has been considered to
be an HCMV-resistant “escape variant,” and the high prevalence
of this allele in multiple populations has been suggested to be
the result of an advantage to human NK cells in recognizing
infected cells. Recently, however, it has been shown that the US9
gene product of HCMV can selectively downregulate MICA*008
expression in a mechanism that depends on specific interference
with the particular cell biology of thisMICA allele (7). This obser-
vation exemplifies how detailed knowledge of the biochemistry of
individual NKG2D-ligands can explain specific functional inter-
actions of these molecules. US9 retention occurs in the ER com-
partment, in which the MICA*008 protein would be transferred
to the GPI moiety (7), while UL142 retains MICA in the Golgi
apparatus (16), suggesting different molecular requirements. In
fact, UL142 retains inside the cell both the transmembraneMICA
alleles and the GPI-anchored protein ULBP3. The use of cell lines
susceptible to HCMV infection, but deficient in GPI-transferase
enzymes (19, 20), could help to identify whether the GPI anchor is
necessary forMICA*008 downregulation byUS9 or themolecular
mechanism for retention depends on another part of themolecule.
Moreover, the information on viral escape and cellular biology
of NKG2D-ligands could be applied in other systems in which
we still need to understand the role of these molecules, mainly
cancer.
Toward Therapies Based on NKG2D
Receptor and its Ligands: The Need for
Personalized Medicine
That MICA*008 has different biochemical features to transmem-
brane MICA alleles leads to at least three important conse-
quences: MICA*008 is released preferentially in exosomes, it has
a very slow maturation process, and it is not affected by other
MICA-modulating pathogen molecules (proteins or miRNAs). It
is entirely plausible that in stressed systems, like cancer cells or
autoimmunity, certain cellular routes could be blockedwhile other
routes could be enhanced leading to alterations in intracellular
protein trafficking. In such a case, NKG2D-ligands could change
their expression from intracellular to secreted or appear at the
plasma membrane, and this effect will in turn vary depending
on the particular ligand. Therefore, it would not be advisable
to treat all MICA alleles as biologically equivalent. To interfere
intelligently with NKG2D-ligand expression, or to interpret ade-
quately the significance of their expression, will require specific
evaluation for each individual patient, determining MICA typ-
ing, the amount of ligands released to serum, and the levels of
NKG2D receptor on their immune cells. More research is needed,
in parallel, to better characterize more differences among MICA
alleles and other ligands for NKG2D. In the meantime, it may
be worthwhile to revisit the results of previous clinical assays
adjusting the data to take into account the MICA typing of the
patients, since it might be better to evaluate MICA behavior in
function of transmembrane versus GPI-anchored.
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